newsfilter
← Latest News
GlobeNewswire·

Traws Pharma Provides Business Highlights and Reports Q1 2026 Financial Results

TRAW
  • Traws Pharma secured up to $60 million in private financing on April 15, 2026, including $10 million in upfront proceeds & milestone-based warrants to fund operations into Q1 2027.
  • The company is advancing tivoxavir marboxil (TXM) toward a human influenza challenge trial in Q2 2026 as a once-monthly prophylactic agent.
  • Traws is actively working with the FDA to resolve a clinical hold on TXM caused by toxicology data concerns, aiming to enable global studies by year-end 2026.
  • The company is developing a new clinical candidate for the treatment of hantavirus infections following recent outbreaks.
  • Q1 2026 revenue was $0.0 million, while research & development expenses rose to $4.9 million & general & administrative expenses fell to $2.0 million.
  • The net loss for the quarter ended March 31, 2026, was $7.1 million, or $0.53 per share, compared to a net income of $21.5 million in the same period in 2025.
  • Cash & cash equivalents stood at approximately $3.1 million as of March 31, 2026, excluding the recently completed financing proceeds.
  • A Phase 1 Bridging Study in Australia is ongoing to evaluate if the compressed tablet formulation of TXM provides 28 days of coverage.
  • Traws plans to conduct a single-dose influenza challenge trial at hVIVO in the UK following MHRA approval & completion of the bridging study.
  • The company has 15,150,669 shares of common stock outstanding as of May 12, 2026.